Levi & Korsinsky Investigates Possible Securities Fraud Violations by Atara Biotherapeutics, Inc. (ATRA)
Portfolio Pulse from
Levi & Korsinsky is investigating Atara Biotherapeutics for potential securities fraud following the FDA's Complete Response Letter regarding their EBVALLOTM treatment.
January 22, 2025 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Atara Biotherapeutics is under investigation for potential securities fraud after receiving a Complete Response Letter from the FDA for their EBVALLOTM treatment.
The investigation by Levi & Korsinsky into Atara Biotherapeutics for possible securities fraud is significant, especially following the FDA's Complete Response Letter. This could negatively impact investor confidence and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100